Photo: Courtesy of Eli Lilly

18 July 2017Americas

Eli Lilly settles Cialis patent litigation with generic makers

Eli Lilly has entered into a settlement agreement with generic companies Teva Pharmaceuticals and Watson Laboratories to resolve pending patent litigation over its drug Cialis (tadalafil).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Eli Lilly tries to halt another Cialis generic

10 April 2018 Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.

UK Supreme Court invalidates Eli Lilly patent relating to Cialis

27 March 2019 The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More on this story

Eli Lilly tries to halt another Cialis generic

10 April 2018 Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.

UK Supreme Court invalidates Eli Lilly patent relating to Cialis

27 March 2019 The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More on this story

Eli Lilly tries to halt another Cialis generic

10 April 2018 Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.

UK Supreme Court invalidates Eli Lilly patent relating to Cialis

27 March 2019 The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

More features

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bristol Myers Squibb leader named INTA 2025 president

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks